MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced that it presented data from a Phase III pivotal trial of BROVANA™ (arformoterol tartrate) Inhalation Solution at CHEST 2006, the annual meeting of the American College of Chest Physicians (ACCP), in Salt Lake City.
